|
An anaplastic astrocytoma is a high-grade, or malignant, glioma, a tumor of the glial (supportive) tissue of the brain. Anaplastic astrocytoma and glioblastoma multiforme, account for approximately 10 percent of pediatric central nervous system tumors.
|
|
This case illustrates the difficulty in differentiating low grade or benign tumors from anaplastic astrocytoma. Both are in the biologic continuum of astrocytoma subtypes, the most common glial cell neoplasm. Anaplastic astrocytomas occupy an intermediate position between low-grade astrocytoma and glioblastoma multiforme.
|
||
|
60% of low-grade astrocytomas occur in people aged 20-45 years; and 30% of low-grade astrocytomas occur in people older than 45 years. The mean age of patients undergoing a biopsy of anaplastic astrocytoma is 41 years.
|
||
|
The designation of a tumor as anaplastic astrocytoma (AA) reflects a distinct histologic classification of malignant glioma characterized by an abundance of pleomorphic astrocytes with evidence of mitosis. ... The Medscape Journal ... Allergy & Clinical Immunology...
|
||
|
METHODS: Conditional survival rate was estimated in 114 consecutive patients with anaplastic astrocytoma or glioblastoma multiforme. Conditional probabilities of surviving some years given survival to a specific period of time after craniotomy and 95% confidence intervals were calculated in the individual tumor survivors.
|
||
|
Anaplastic astrocytoma (grade III); Patients with anaplastic astrocytoma often present with seizures, neurologic deficits, headaches, or changes in mental status. The standard initial treatment is to remove as much of the tumor as possible without worsening neurologic deficits.
|
||
|
What is an anaplastic astrocytoma?; What are the symptoms of an anaplastic astrocytoma?; How are anaplastic astrocytomas classified?; How is an anaplastic astrocytoma diagnosed?; What are the treatments for an anaplastic astrocytoma?; How are side effects managed?; What is the expected outcome after treatment...
|
||
|
In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide, Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international ... The response rate for AP 12009 10 μM in anaplastic astrocytoma patients steadily increased in the course of 14 months,
|
||
|
An astrocytoma is a glioma that develops from star-shaped glial cells (astrocytes) that support nerve cells. An anaplastic astrocytoma is classified as a grade III tumor.
|
Related Searches
Ask Q&A
Featured Theme
This binocular preview is a sneak peek of the Web page behind this search result. If the image says "Site Home Page" we are showing you a preview of the website's home page because we still have to update our binocular system with the particular page from your search result. The text at the bottom of the preview gives you more details, such as:
- Whether the page requires plug-ins such as Flash
- Whether the page will "pop up" additional windows upon loading
- How much data you'll have to download to view the complete page
- How long it should take for you to download the full page, based on a 56 kb/s dial-up Internet connection